Recruiting

ACTengine® IMA203/​IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/​or Refractory Solid Tumors (ACTengine) – NCT03686124

This Phase 1 clinical trial is investigating a personalised T-cell therapy called IMA203 (also known as anzutresgene autoleucel) for people with advanced solid tumours, including metastatic uveal melanoma. IMA203 is a type of immunotherapy designed to genetically modify a patient’s own immune cells (T cells) so they can better recognise and attack cancer cells carrying […]

ACTengine® IMA203/​IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/​or Refractory Solid Tumors (ACTengine) – NCT03686124 Read More »

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma (NBM-BMX-UM

This Phase 1/2 clinical trial is investigating a new targeted treatment called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body. NBM-BMX is designed to target a pathway involved in tumour growth and cancer cell survival, with researchers hoping it may help slow

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma (NBM-BMX-UM Read More »

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)

This Phase 3 clinical trial, known as PRISM-MEL-301, is investigating whether a new immunotherapy treatment called brenetafusp (IMC-F106C), given in combination with nivolumab, works better than standard nivolumab-based treatment for people with advanced melanoma that cannot be removed surgically or has spread to other parts of the body. The study is specifically for patients who

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301) Read More »

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/​11 Mutations or PRKC Fusions

This Phase 1/2 clinical trial is investigating the safety and effectiveness of a targeted treatment combination using darovasertib (IDE196) and crizotinib in people with metastatic uveal melanoma. Darovasertib is a protein kinase C (PKC) inhibitor designed to target genetic pathways commonly involved in uveal melanoma, while crizotinib targets another pathway linked to tumour growth. Researchers

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/​11 Mutations or PRKC Fusions Read More »

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors – NCT07070232

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors – NCT07070232 Read More »

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801 alone and with Pembrolizumab – NCT04130516

This Phase 1/2, first-in-human, open-label, multicenter study aims to determine the safest and most effective dose (Maximum Tolerated Dose, MTD, or Recommended Phase 2 Dose, RP2D) of LNS8801, both on its own and in combination with pembrolizumab. Using a 3+3 dose escalation design, the study will evaluate the safety, tolerability, how the drug behaves in

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801 alone and with Pembrolizumab – NCT04130516 Read More »

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) – Master Screening Protocol (DETERMINE) – NCT05722886

DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Participants must have a cancer with an identified mutation. This could be found during routine testing or as part of another research programme.

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) – Master Screening Protocol (DETERMINE) – NCT05722886 Read More »

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass) – NCT06007690

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass) – NCT06007690 Read More »

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) – NCT05315258

Researchers are exploring better ways to manage people with intermediate or high-risk resected cutaneous melanoma or primary uveal melanoma. This study is investigating the use of a new blood test to guide when to administer a drug called tebentafusp. Tebentafusp has previously been tested in clinical trials for patients with advanced cutaneous and uveal melanoma.

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) – NCT05315258 Read More »